期刊文献+

贲门癌组织中sPLA2(Ⅱa)的表达

Expression of sPLA2(Ⅱa) protein in gastric cardia adenocarcinoma tissue
下载PDF
导出
摘要 目的探讨河南贲门癌高发区贲门癌组织中sPLA2(Ⅱa)的表达。方法采用免疫组化卵白素-生物素-过氧化物酶复合物(ABC)法分析80例贲门癌组织和16例贲门癌旁肠化组织中sPLA2(Ⅱa)的表达情况。结果sPLA2(Ⅱa)在癌旁肠化组织中的表达高于贲门腺癌组织(75.0%vs37.5%,P<0.05),高、中、低分化贲门腺癌sPLA2(Ⅱa)阳性率分别为38.5%、27.6%、48.0%,三组表达率差异无统计学意义(P>0.05)。结论sPLA2(Ⅱa)可能参与了贲门癌的癌变过程。 Objective To characterize the alterations of sPLA2(Ⅱ a) in gastric cardiac adenoeareinoma(GCA) from the high-incidence area for GCA in Henan. Methods sPLA2 ( Ⅱa) expression was detected by immunohistoehemieal method (ABC) in 80 GCA patients and 16 cases with intestinal metaplasia(IM) adjacent to gastric eardia adenoeareinoma (GCA). Results The positive rate of sPLA2 ( Ⅱ a) in intestinal metaplasia was higher than that in GCA (75.0% vs 37.5% ,P 〈 0.05). The positive sPLA2 ( Ⅱ a) expression in advanced, moderately differentiated and poorly differentiated GCA were 38.5% , 27.6% , 48.0% , respectively, and the difference was not significant( P 〉0.05 ). Conclusion sPLA2( Ⅱ a) may play an important role in the carcinogenesis of GCA.
出处 《胃肠病学和肝病学杂志》 CAS 2008年第7期588-590,共3页 Chinese Journal of Gastroenterology and Hepatology
基金 国家科技部863重大专项(2006AA02A403)
关键词 贲门腺癌 肠化 分泌型磷脂酶A2 Gastric cardia adenocarcinoma Intestinal metaplasia sPLA2 (Ⅱ a)
  • 相关文献

参考文献14

  • 1Guanrei Y, Sunglian Q. Incidence rate of adenocarcinoma of the gastric cardia and endoscopic classification of early cardial carcinoma in Henan Province, the People's Republic of China[ J]. Endoscopy, 1987, 19 (1): 7-10.
  • 2Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites[J]. Br J Cancer, 1990, 62(3 ) : 440-443.
  • 3张梅,王立东,王俊宽,郭涛,冯笑山,李寒冰,李琮宇,李吉林,焦新英,范宗民,何欣,樊慧,申秋,郭军辉,罗平,王能超,吴爱群,邢国兰.贲门癌癌组织中环氧合酶-2蛋白的表达[J].郑州大学学报(医学版),2007,42(3):417-418. 被引量:3
  • 4王立东,刘宾,郭瑞锋,白永敏,孙超,益新娜,贺新伟,谢冬岭,范宗民,丁忠华.河南食管癌高发区居民食管和贲门上皮癌变过程中C-erbB2和c-myc表达的变化[J].郑州大学学报(医学版),2002,37(6):739-742. 被引量:26
  • 5Murakami M, Kudo I. Phospholipase A2[J]. J Biochem, 2002, 131 ( 3 ) : 285-292.
  • 6Dong Q, Patel M, Scott KF, et al. Oncogenic action of phospholipase A2 in prostate cancer [J]. Cancer Lett, 2005, 240(1): 9-16.
  • 7梁宁生,方珍文.血小板型磷脂酶A_2与肿瘤的关系[J].中国癌症杂志,2002,12(6):555-558. 被引量:6
  • 8Masuda S, Murakami M, Ishikawa Y, et al. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues [J]. Biochim Biophys Acta, 2005, 1736(3): 200-210.
  • 9Huhtinen HT, Gronroos JM, Haapamaki MM, et al. Source of group Ⅱ phospholipase A2 in gastric juice[ J]. Scand J Clin Lab Invest, 2002,62(2) : 123-128.
  • 10Tribler L, Jensen LT, JO rgensen K, et al. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue [ J ]. Anticancer Res, 2007, 27 (5A) : 3179-3185.

二级参考文献26

  • 1凌桂琴,王绪.COX-2与肿瘤[J].徐州医学院学报,2005,25(3):271-274. 被引量:4
  • 2Dennis EA. Diversity of grouptypes,regulation,and function of phospholipase A2 [ J ]. J Biol Chem, 1994,269 ( 18 ):13057-13060
  • 3Papanikolaou A, Wang QS, Mulherkar R, et al. Expression analysis of the group Ⅱ Asecretory phospholipase A(2) in mice with differential susceptibility toazoxymethane-induced colon tumorigenesis[ J]. Carcinogenesis,2000,21 (2): 133-138.
  • 4Cormier RT, Bilger A, Lillich AJ, et al. The Moml AKR intestinal tumor resistanceregion consists of Pla2g2a and a locus distal to D4Mit64[J]. Oncogen,2000,19(28):3182-3192.
  • 5Graff JR, Konicek BW, Deddens JA,et al. Expression of group Ⅱ a secretoryphospholipase A2 increases with prostate tumor grade [ J ]. Clin Cancer Res,2001,7 ( 12 ):3857-3861.
  • 6MacPhee M, Chepenlk KP, Liddell RA, et al. The secretory phospholipase A2 gene is acandidate for the Moml locus, a major modifier of APCMin-induced intestinal neoplasia [J]. Cell,1995,81 (6) :957-966.
  • 7Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC[J].Hum Mol Genet,2001,10(7 ):721-733.
  • 8Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confersresistance to intestinal tumorigenesis [ J ]. Nature Genet, 1997,17 ( 1 ): 88-91.
  • 9Cormier RT, Dove WF. Dnmt 1 N/+ reduces the net growth rate and multiplicity ofintestinal adenomas in C57BL/6-multiple intestinal neoplasia ( min)/+ mice independentlyof p53 but demonstrates strong synergy with the modifier of min 1 ( AKR )resistance allele[ J ]. Cancer Res,2000,60 ( 14 ): 3965-3970.
  • 10Halberg RH, Katzung DS, Hoff PD, et al. Tumorigengsis in the multiple intestinalneoplasia mouse: redundancy of negative regulators and specificity of modifiers [ J ].Proc Natl Acad Sci USA, 2000,28 ( 7 ): 3461-3466.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部